Coronary Artery Disease Aspirin 75-100 mg/d
√ (1A) √ (2A)
√ if VKA monitoring is difficult (2A)
major √ (2A) sk for √ (2B) √ (2B)
√ indefinitely and 75-162 mg initially (1A)
√
√ x 2-4 weeks (1A) ≤ 12 months (2B)
300 mg oral loading dose (2B) 75 mg loading dose (2B)
√ x 12 months (1A) if tolerated √ x 12 months √ x ≥ 3 months
√ x 12 months3 √ x 3-12 months
√
√ indefinitely (1A) and postoperatively (2A)
√ x 9-12 months
√ 75-162 mg indefinitely (1A)
None (1B)
y issues (2C). is, and a lower value on minimizing bleeding risk. clopidine (1A). ding clopidogrel†
lation and a history of a thromboembolic event. (1B).
nary events and deaths and a relatively high value on avoiding the inconvenience, cost, and minor bleeding risk associated with to 3 months and is associated with lower risk of bleeding. Patients, particularly those in the highest risk groups for whom systems uctions in coronary events and are not influenced by an element of inconvenience and potential bleeding risk associated with VKA are
to aspirin and a low value on avoiding the additional bleeding and high cost associated with clopidogrel† .
√ x 12 months √ x 3-12 months
√ x 4 weeks aſter BMS √ x 12 months aſter DES
Discontinue for 5 days (2A)
For aspirin allergy — 300 mg loading dose 6 h aſter operation followed by 75 mg/d PO indefinitely (1B)
√ x 9-12 months
None if no other indication (1C) None (1B)
None if no other indication (1C) Suggested for other indications such as heart valve replacement (2C)
None (1A) √
Moderate-intensity oral VKA (target INR, 2.5; range 2.0 to 3.0) x ≥ 3 months
Clopidogrel†
75 mg/d
Aspirin allergy who are at moderate to high risk (1B)
Possibly add (2A)
Low-dose oral VKA (target INR, 1.5) if monitoring is easy (2A)
VKAs
√ (2B) None (1B) unless high risk1
High-intensity oral VKA (target INR, 3.5; range, 3.0 to 4.0)
Moderate-intensity oral VKA (target INR, 2.5; range 2.0 to 3.0)
